Samuel Levine, Director of the Federal Trade Commission’s Bureau of Consumer Protection, has commented on a recent court ruling involving the dietary supplement Prevagen. The U.S. District Court for the Southern District of New York has ordered the makers of Prevagen to stop making claims deemed deceptive in a lawsuit filed by the FTC and New York Attorney General.

"Following seven years of hard-fought litigation, including a jury trial, we are pleased that the Court has ordered Quincy Bioscience to cease making claims about Prevagen that mislead Americans concerned about memory loss," Levine stated. He emphasized that companies must ensure health claims are supported by reliable scientific evidence.

This decision marks another victory in the FTC's ongoing efforts to safeguard older consumers. Last month, the agency introduced new measures against tech support scams targeting this demographic. More details can be found in their Protecting Older Consumers Report.

The Federal Trade Commission continues its mission to promote competition and protect consumers through education and enforcement actions. They remind individuals that they will never demand money or make threats and encourage reporting fraud at ReportFraud.ftc.gov. For more information on consumer issues, visit consumer.ftc.gov.